These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 31580253)

  • 1. What are the Characteristics of Patients Experiencing Adverse Drug Reactions to Oral Anticogulants and How Can Such Reactions be Prevented?
    Spada G; Vighi GV; Pagani S; Vighi GD; Venegoni M; Ruocco M
    Curr Drug Saf; 2020; 15(1):38-44. PubMed ID: 31580253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preventability of serious thromboembolic and bleeding events related to the use of oral anticoagulants: a prospective study.
    Sennesael AL; Larock AS; Devalet B; Mathieux V; Verschuren F; Muschart X; Dalleur O; Dogné JM; Spinewine A
    Br J Clin Pharmacol; 2018 Jul; 84(7):1544-1556. PubMed ID: 29522647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug reactions with oral anticoagulants: data from sicilian spontaneous reporting system database.
    Barbieri MA; Cutroneo PM; Baratelli C; Cicala G; Battaglia A; Santoro V; Andò G; Spina E
    J Clin Pharm Ther; 2021 Aug; 46(4):1027-1040. PubMed ID: 33646603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical profile of direct oral anticoagulants versus vitamin K anticoagulants in octogenarians with atrial fibrillation: a multicentre propensity score matched real-world cohort study.
    Russo V; Attena E; Di Maio M; Mazzone C; Carbone A; Parisi V; Rago A; D'Onofrio A; Golino P; Nigro G
    J Thromb Thrombolysis; 2020 Jan; 49(1):42-53. PubMed ID: 31385163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Benefit of Direct Oral Anticoagulants Versus Vitamin K Antagonists in Patients with Atrial Fibrillation and Bioprosthetic Heart Valves.
    Russo V; Carbone A; Attena E; Rago A; Mazzone C; Proietti R; Parisi V; Scotti A; Nigro G; Golino P; D'Onofrio A
    Clin Ther; 2019 Dec; 41(12):2549-2557. PubMed ID: 31735436
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of hospital admissions due to adverse drug reactions in France: the EMIR study.
    Bénard-Laribière A; Miremont-Salamé G; Pérault-Pochat MC; Noize P; Haramburu F;
    Fundam Clin Pharmacol; 2015 Feb; 29(1):106-11. PubMed ID: 24990220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Anticoagulant Agents: Incidence of Adverse Drug Reactions and New Signals Thereof.
    Treceño-Lobato C; Jiménez-Serranía MI; Martínez-García R; Corzo-Delibes F; Martín Arias LH
    Semin Thromb Hemost; 2019 Mar; 45(2):196-204. PubMed ID: 29864777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of Cardiovascular Events and Mortality Among Elderly Patients With Reduced GFR Receiving Direct Oral Anticoagulants.
    Ashley J; McArthur E; Bota S; Harel Z; Battistella M; Molnar AO; Jun M; Badve SV; Garg AX; Manuel D; Tanuseputro P; Wells P; Mavrakanas T; Rhodes E; Sood MM
    Am J Kidney Dis; 2020 Sep; 76(3):311-320. PubMed ID: 32333946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case fatality of bleeding and recurrent venous thromboembolism during, initial therapy with direct oral anticoagulants: a systematic review.
    Wu C; Alotaibi GS; Alsaleh K; Sean McMurtry M
    Thromb Res; 2014 Sep; 134(3):627-32. PubMed ID: 25047174
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse drug reactions to anticoagulants in Spain: analysis of the Spanish National Hospital Discharge Data (2010-2013).
    Carrasco-Garrido P; Hernández-Barrera V; Esteban-Hernández J; Jiménez-Trujillo I; Álvaro-Meca A; López de Andrés A; de Miguel Diez J; Rodríguez Barrios JM; Muñoz Robles JA; Jiménez-García R
    BMJ Open; 2017 Jan; 7(1):e013224. PubMed ID: 28073793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases.
    Maura G; Billionnet C; Alla F; Gagne JJ; Pariente A
    Pharmacotherapy; 2018 Jan; 38(1):6-18. PubMed ID: 29028119
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with non-valvular atrial fibrillation on vitamin k antagonists or direct-acting oral anticoagulants: patients profile and long-term follow up outcomes.
    Sigismondi A; Camacho-Freire SJ; León-Jiménez J; Isasti-Aizpurva G; García-Lizana MD; Morgado-García de Polavieja JI; Caro-Fernández FJ; Roa-Garrido J; Navarro-Roldán F; Díaz-Fernández JF
    Arch Cardiol Mex; 2019; 89(4):382-392. PubMed ID: 31834326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major bleeding with vitamin K antagonists or direct oral anticoagulants in real-life.
    Becattini C; Franco L; Beyer-Westendorf J; Masotti L; Nitti C; Vanni S; Manina G; Cattinelli S; Cappelli R; Sbrojavacca R; Pomero F; Marten S; Agnelli G
    Int J Cardiol; 2017 Jan; 227():261-266. PubMed ID: 27843050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kidney Function Decline and Serious Adverse Drug Reactions in Patients With CKD.
    Laville SM; Gras-Champel V; Hamroun A; Moragny J; Lambert O; Metzger M; Jacquelinet C; Combe C; Fouque D; Laville M; Frimat L; Robinson BM; Bieber B; Stengel B; Alencar De Pinho N; Massy ZA; Liabeuf S;
    Am J Kidney Dis; 2024 May; 83(5):601-614.e1. PubMed ID: 37951340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors Associated With the Choice of Oral Anticoagulant Class in the Older Patients: An Observational Study.
    Pagès A; Sabatier R; Sallerin B
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):332-337. PubMed ID: 32266832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Under-reporting of adverse drug reactions, a problem that also involves medicines subject to additional monitoring. Preliminary data from a single-center experience on novel oral anticoagulants].
    Patrignani A; Palmieri G; Ciampani N; Moretti V; Mariani A; Racca L
    G Ital Cardiol (Rome); 2018 Jan; 19(1):54-61. PubMed ID: 29451510
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse drug reaction-related hospitalisations: a nationwide study in The Netherlands.
    van der Hooft CS; Sturkenboom MC; van Grootheest K; Kingma HJ; Stricker BH
    Drug Saf; 2006; 29(2):161-8. PubMed ID: 16454543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Better clinical outcome with direct oral anticoagulants in hospitalized heart failure patients with atrial fibrillation.
    Yoshihisa A; Sato Y; Sato T; Suzuki S; Oikawa M; Takeishi Y
    BMC Cardiovasc Disord; 2018 Jan; 18(1):11. PubMed ID: 29368593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of Direct Oral Anticoagulants and Vitamin K Antagonists in Oldest Old Patients: A Prospective Study.
    Rodríguez-Pascual C; Torres-Torres I; Gómez-Quintanilla A; Ferrero-Martínez AI; Sharma J; Guitián A; Basalo MC; Montero-Magan M; Vilches-Moraga A; Olcoz-Chiva MT; Paredes-Galán E; Rodríguez-Artalejo F
    J Am Med Dir Assoc; 2018 Nov; 19(11):936-941. PubMed ID: 29891182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIIA Study.
    Ortiz MR; Muñiz J; Esteve-Pastor MA; Marín F; Roldán I; Cequier A; Martínez-Sellés M; Saldivar HG; Bertomeu V; Anguita M
    J Cardiovasc Pharmacol Ther; 2020 Jul; 25(4):316-323. PubMed ID: 32228180
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.